Memgen, Inc.

Memgen, Inc. is a clinical-stage biotech company with the vision of developing life-saving cancer immunotherapies. They focus on harnessing the power of the immune system to potentially cure cancer and protect people from infectious diseases. Memgen's pipeline products utilize its proprietary CD40L transgene, MEM40, known for eliciting powerful, antigen-specific immune responses.

The company's lead cancer immunotherapy, MEM-288, developed in collaboration with Moffitt Cancer Center, is an oncolytic virus engineered to selectively target cancer cells and supercharge the immune system through the expression of two unique and powerful immune modulators: MEM40 and the powerful cytokine interferon beta. Memgen is close to completing the monotherapy part of a clinical trial in advanced/metastatic NSCLC.

Memgen's vaccine adjuvant, MemVax, is designed to be used in combination with other vaccines to generate a strong, durable immune response. It is a highly specific immune stimulant that can work with antigens across a range of delivery approaches. The company has over 100,000 doses of MemVax ready to go into clinical trials, along with an active file with the US FDA. They plan to begin clinical trials of MemVax in collaboration with other companies developing complementary vaccines.

Founded in 2004, Memgen, Inc. operates within the biotechnology, health care, life sciences, and pharmaceutical industries. The company received a Venture - Series Unknown investment on 17 November 2022.